Erika López-Arribillaga

Dr. Erika López-Arribillaga


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2011 in Oncogene
Verified
Journal Article
Closed access
PDF file
OLO Leis
O Leis
AEA Eguiara
A Eguiara
ELErika López-Arribillaga
Erika López-Arribillaga
MAM J Alberdi
M J Alberdi
SHS Hernandez-Garcia
S Hernandez-Garcia
AMA G Martin
A G Martin

1 January 2015 in Development
Verified
Journal Article
Open access
PDF file
ELErika López-Arribillaga
Erika López-Arribillaga
VRVeronica Rodilla
Veronica Rodilla
LPLuca Pellegrinet
Luca Pellegrinet
JGJordi Guiu
Jordi Guiu
MIMar Iglesias
Mar Iglesias
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Genetic data indicate that abrogation of Notch-Rbpj or Wnt-β-catenin pathways results in the loss of the intestinal stem cells (ISCs). However, whether the effect of Notch is direct or due to the aberrant differentiation of the transit-amplifying cells into post-mitotic goblet cells is unknown. To address this issue, we have generated composite tamoxifen-inducible intestine-specific genetic mouse models and analyzed the expression of intestinal differentiation markers. Importantly, we found that activation of β-catenin partially rescues the differentiation phenotype of Rbpj deletion mutants, but not the loss of the ISC compartment. Moreover, we identified Bmi1, which is expressed in the ISC and progenitor compartments, as a gene that is co-regulated by Notch and β-catenin. Loss of Bmi1 resulted in reduced proliferation in the ISC compartment accompanied by p16INK4a and p19ARF (splice variants of Cdkn2a) accumulation, and increased differentiation to the post-mitotic goblet cell lineage that partially mimics Notch loss-of-function defects. Finally, we provide evidence that Bmi1 contributes to ISC self-renewal.

23 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLaura Solé
Laura Solé
TLTeresa Lobo-Jarne
Teresa Lobo-Jarne
DÁDaniel Álvarez-Villanueva
Daniel Álvarez-Villanueva
JAJosune Alonso-Marañón
Josune Alonso-Marañón
YGYolanda Guillén
Yolanda Guillén
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.

1 August 2013 in Cancer Cell
Verified
Journal Article
Closed access
MMMaría Carmen Mulero
María Carmen Mulero
DFDolors Ferres-Marco
Dolors Ferres-Marco
AIAbul Islam
Abul Islam
PMPol Margalef
Pol Margalef
MPMatteo Pecoraro
Matteo Pecoraro
Lluis EspinosaLluis Espinosa
Lluis Espinosa

2 December 2019 in Nature Cancer
Verified
Journal Article
Open access
PDF file
FMFrancisco Martínez-Jiménez
Francisco Martínez-Jiménez
FMFerran Muiños
Ferran Muiños
ELErika López-Arribillaga
Erika López-Arribillaga
NLNuria Lopez-Bigas
Nuria Lopez-Bigas
AGAbel Gonzalez-Perez
Abel Gonzalez-Perez
E3 ligases and degrons, the sequences they recognize in target proteins, are key parts of the ubiquitin-mediated proteolysis system. There are several examples of alterations of these two components of the system that have a role in cancer. Here we uncover the landscape of the contribution of such alterations to tumorigenesis across cancer types. We first systematically identified new instances of degrons across the human proteome by using a random forest classifier and validated the functionality of a dozen of them, exploiting somatic mutations across >7,000 tumors. We detected signals of positive selection across known and new degron instances. Our results reveal that several oncogenes are frequently targeted by mutations that affect the sequence of their degrons or their cognate E3 ubiquitin ligases, causing an abnormal increase in their protein abundance. Overall, an important number of driver mutations across primary tumors affect either degrons or E3-ubiquitin ligases.

31 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ELErika López-Arribillaga
Erika López-Arribillaga
VRVeronica Rodilla
Veronica Rodilla
CCCarlota Colomer
Carlota Colomer
AVAnna Vert
Anna Vert
ASAmy Shelton
Amy Shelton
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates Notch in intestinal adenomas carrying active β-catenin. We used the ApcMin/+ mouse model, tumor spheroid cultures, and patient-derived orthoxenografts to address this divergent ligand-dependent Notch function and its implication in disease. We found that intestinal-specific Jag1 deletion or antibody targeting Jag1 prevents tumor initiation in mice. Addiction to Jag1 is concomitant with the absence of Manic Fringe (MFNG) in adenoma cells, and its ectopic expression reverts Jag1 dependence. In 239 human colorectal cancer patient samples, MFNG imposes a negative correlation between Jag1 and Notch, being high Jag1 in the absence of MFNG predictive of poor prognosis. Jag1 antibody treatment reduces patient-derived tumor orthoxenograft growth without affecting normal intestinal mucosa. Our data provide an explanation to Jag1 dependence in cancer, and reveal that Jag1–Notch1 interference provides therapeutic benefit in a subset of colorectal cancer and FAP syndrome patients.